Fundraising FoxBrainStorm Cell Therapeutics
Hackensack, US · 1 known investors
Find your way into BrainStorm Cell Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
211 people can intro you to Uri
Ask Liat Soffer to introduce you to Uri Yablonka
You →Liat · together at BrainStorm Cell Therapeutics →Uri
Sign up to find every way you can get introduced to BrainStorm Cell Therapeutics
- Your email: who you already know at BrainStorm Cell Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the BrainStorm Cell Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
BrainStorm Cell Therapeutics develops NurOwn, an autologous MSC-NTF cellular therapy platform aimed at treating neurodegenerative diseases with limited treatment options. Its cell therapy is investigational and not yet FDA approved.
Founders & leadership
AF
Anthony FiorinoExecutive
UY
Uri YablonkaExecutive Director & EVP, Chief Business OfficerUri Yablonka is an executive at BrainStorm Cell Therapeutics with over 15 years of biotech experience spanning clinical development, regulatory, and operations. He holds an LL.M in Commercial Law and has a background in journalism and legal consulting.
LS
Liat SossoverExecutive
IA
Irit ArbelNamed on SEC filing
Board
MF
Mordechai FriedmanBoard director
AP
Alon PinkasBoard director
CS
Chen SchorBoard director
RS
Robert ShorrBoard director
MS
Malcolm S. TaubBoard director
Investors · 1
Funding
SEC filings, press & company announcements$12.1M disclosed across 2 of 6 rounds · 2014–2026
- Undisclosed amountprivate placementFeb 2026Source ↗
▶Undisclosed amountofferedAug 2019 · 3 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedAug 2019 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ralph KernExecutive Officer
- Dr. Anthony PolverinoDirector
- Chen SchorDirector
- Arturo ArayaExecutive Officer
- Dr. June AlmenoffDirector
- Dr. Irit ArbelDirector
- Malcolm TaubDirector
- Chaim LebovitsExecutive Officer
- Eyal RubinExecutive Officer
- Uri YablonkaExecutive Officer, Director
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedJun 2018 · 6 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJun 2018 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Anthony PolverinoDirector
- Uri YablonkaExecutive Officer, Director
- Chaim LebovitsExecutive Officer
- Ralph KernExecutive Officer
- Dr. June AlmenoffDirector
- Dr. Irit ArbelDirector
- Arturo ArayaDirector
- Eyal RubinExecutive Officer
- Chen SchorDirector
- Malcolm TaubDirector
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedJan 2015 · 8 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedJan 2015 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mordechai FriedmanDirector
- Anthony FiorinoExecutive Officer
- Alon PinkasDirector
- Uri YablonkaExecutive Officer, Director
- Irit ArbelDirector
- Liat SossoverExecutive Officer
- Chen SchorDirector
- Chaim LebovitsExecutive Officer
- Robert ShorrDirector
- Malcolm S. TaubDirector
- Sales commissions
- $817.6K
- Placement agents
- Maxim Group LLC
- First sale
- Jan 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10.5MraisedJul 2014 · 11 investors · BiotechnologyRule 506(b)
▶$10.5MraisedJul 2014 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Malcolm S. TaubDirector
- Liat SossoverExecutive Officer
- Alon PinkasDirector
- Chaim LebovitsExecutive Officer
- Irit ArbelDirector
- Anthony FiorinoExecutive Officer
- Mordechai FriedmanDirector
- Chen SchorDirector
- Uri YablonkaExecutive Officer, Director
- Robert ShorrDirector
- Offering amount
- $10.5M
- Amount sold
- $10.5M
- Sales commissions
- $724.5K
- Placement agents
- Maxim Group LLC
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.6MraisedMay 2014 · 8 investors · BiotechnologyRule 506(b)
▶$1.6MraisedMay 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Liat SossoverExecutive Officer
- Malcolm TaubDirector
- Robert ShorrDirector
- Chaim LebovitsExecutive Officer
- Alon PinkasDirector
- Mordechai FriedmanDirector
- Chen SchorDirector
- Irit ArbelDirector
- Offering amount
- $2.5M
- Amount sold
- $1.6M
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through BrainStorm Cell Therapeutics went on to found or lead other companies.
Related companies · 6
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
FoxbusinessFOX Business Network is a financial news channel that delivers real-time business and market information across multiple platforms. The network serves investors and business audiences interested in news affecting both retail and institutional markets.
Companies working in the same space as BrainStorm Cell Therapeutics.
In the news
Frequently asked questions
- What does BrainStorm Cell Therapeutics do?
- BrainStorm Cell Therapeutics develops NurOwn, an autologous MSC-NTF cellular therapy platform aimed at treating neurodegenerative diseases with limited treatment options. Its cell therapy is investigational and not yet FDA approved.
- Who are BrainStorm Cell Therapeutics's investors?
- BrainStorm Cell Therapeutics's investors include Abbhi Capital.
- How much funding has BrainStorm Cell Therapeutics raised?
- BrainStorm Cell Therapeutics has disclosed $12.1M raised across 2 of its 6 known rounds.
- Where is BrainStorm Cell Therapeutics headquartered?
- BrainStorm Cell Therapeutics is headquartered in Hackensack, US.